Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04123314 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Name: Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease — clinical trial record (NCT04123314)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseEarly Phase 1

SponsorJohns Hopkins University

Started2021-03-24

View on ClinicalTrials.gov ↗

This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.

Amendment history 2 changes detected by DataLookout

2026-09-05

Primary completion pushed: 2026-09-30 → 2027-06-30

2026-09-05

Completion pushed: 2026-12-31 → 2027-09-30

Trial Details

NCT Number	NCT04123314
Lead Sponsor	Johns Hopkins University Collaborators: Council On Spiritual Practices, Heffter Research Institute
Conditions	Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Enrollment	20 participants
Start Date	2021-03-24
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-04